Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Angioguard distal protection device, PTCA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | PTCA |
| 2 | OTHER | PTCA with angioguard |
| Name | Type | Description |
|---|---|---|
| Angioguard distal protection device | DEVICE | PTCA with the Angioguard distal protection device. |
| PTCA | OTHER | PTCA |
Inclusion Criteria: * Acute myocardial infarction \< 12 hours with ST segment elevation \> 2 mm in at least 2 contiguous leads; * Clinical indication of primary PTCA; * De novo or restenotic lesions in native coronary vessel, single vessel treatment only; * Target lesion stenosis is \> 80% (by visu...
Angioguard distal protection device, PTCA is used for Coronary Artery Disease. It is a distal protection device intended for use during percutaneous transluminal coronary angioplasty (PTCA) in patients with acute myocardial infarction. The device is designed to capture debris during the procedure.
Angioguard distal protection device, PTCA is developed by Cardinal Health, Inc., a company traded on the New York Stock Exchange under the ticker CAH. Cardinal Health is the developer of this investigational device for use in coronary artery disease procedures.
Angioguard distal protection device, PTCA is in Phase 2 clinical development. It is an investigational device and has not been approved by the FDA. The device is being studied for its safety and effectiveness in patients with coronary artery disease undergoing PTCA.
Angioguard distal protection device, PTCA has one completed clinical trial, NCT00264030, titled "Distal Protection Combined With PTCA in AMI Patients." This Phase 2 trial enrolled 56 participants in France and studied the device in patients with coronary artery disease. The trial was controlled and randomized.
Angioguard distal protection device, PTCA is a specific version of the Angioguard distal protection device, designed for use during percutaneous transluminal coronary angioplasty (PTCA). The name indicates its intended application in coronary artery disease procedures, distinguishing it from other potential uses of the Angioguard platform.